The Viability of Cancerous vs. Non-cancerous Cells

Similar documents
An Automated, Cell-based Platform for the Rapid Detection of Novel Androgen Receptor Modulators

Tips for Multiplexing Cell-Based Assays:

PathHunter β-arrestin Human and Ortholog GPCR Assays

Label-free, real-time live-cell assays for spheroids: IncuCyte bright-field analysis

Z -LYTE fluorescent kinase assay technology. Z -LYTE Kinase Assay Platform

ICSB Workshop: Drug Response Measurement and Analysis Part 2: Best practices for experimental design, execution, and analysis

INTERFERin in vitro sirna/mirna transfection reagent PROTOCOL

superior performance in virtually every application

SUPPLEMENTARY INFORMATION. Small molecule activation of the TRAIL receptor DR5 in human cancer cells

Tecan D300e Digital Dispenser MINIATURIZE YOUR ASSAY

INDIGO Biosciences Nuclear Receptor Reporter Assay Systems

INTERFERin sirna transfection reagent

Determination of Inhibitor Residence Times for a Phosphodiesterase using the Transcreener AMP 2 /GMP 2 FP Assay

Measuring Phosphodiesterase Inhibitor Residence Times with the Transcreener AMP 2 /GMP 2 FP Assay

+ M III. IMAP Screening Express Kit Product #8073 Quantity: 8000, 20 µl reactions (80 µl final volumes) Low FP. M III High FP.

Introduction to Assay Development

THE DELIVERY EXPERTS. INTERFERin in vitro sirna transfection reagent PROTOCOL

In Vitro Angiogenesis Assay Kit

BoTest A/E Botulinum Neurotoxin Detection Kit- Detailed Description

Measurement by Spark 20M / Spark 10M Multimode microplate reader

MicroRNA Analysis Paired with Novel Cell Health Assays: A Complete Workflow

PIPETMAX : Flexible Automated Workflow for Kinase Selectivity Profiling

Calcein AM Cell Viability Kit

MTT-Cell Based Proliferation/Toxicity Assay

ATPlite Assay Performance in Human Primary Cells

The effects of an Unknown Drug on S. Cerevisiae Strain of Yeast Cell Growth Cycles March 1, 2006 Theresa Collins Ana Caputo Scott Cathcart

xcelligence System RTCA HT Instrument

Technical Manual. Transcreener KINASE Assay Transcreener KINASE Plus Assay

Optimizing Dual-Glo Luciferase Assays with the Synergy HT Multi-Detection Microplate Reader

E1 LITE - UBE1 Activity Assay Kit. Catalog Number UC105

Multiplexing Cell-Based Assays:

SensoLyte Homogeneous AFC Caspase-8 Assay Kit *Fluorimetric*

Data Sheet. TGFβ/SMAD Signaling Pathway SBE Reporter HEK293 Cell Line Catalog #: 60653

PolarScreen Tyrosine Kinase Assay Kit, Far Red Protocol

Protocol part no. PV5116.pps Rev. date: 14 April 2008

PromoFectin-siRNA. Instruction Manual

Z -LYTE KINASE ASSAY KIT TYR 3 PEPTIDE PROTOCOL

Part. no. PV4319.pps Rev. date 29 June 2006

RayBio ApoSENSOR TM ATP Cell Viability Assay Kit

PromoFectin-Hepatocyte Cell Transfection Reagent. Instruction Manual. Cat.No. PK-CT-2000-HEP-10 PK-CT-2000-HEP-50

GeneCellin TM HTC Transfection Reagent Protocol vs6 2/12

Morphology and ATP-based Cytotoxicity Profiling of Cancer Cell Lines using the EnSight Multimode Plate Reader with Well Imaging Technology

Cell Health and Viability Assays Real-time automated measurements of cell health and viability inside your incubator

Performance of cell viability and cytotoxicity assays on the IN Cell Analyzer 3000

Part Number: GY-SMPE010. Smart PEI. Instructions for Use. For research use only. Not for use in humans.

SensoLyte Homogeneous AFC Caspase-8 Assay Kit *Fluorimetric*

RealTime-Glo MT Cell Viability Assay

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Optimization of a LanthaScreen Kinase assay for BRAF V599E

Assay Name: Antibody-Dependent Receptor Internalization Assay

Mitochondrial Biogenesis Assay after 5-day Treatment in PC-3 Cells Yili Xu and Joy Y. Feng *

Assessment of HDAC1 Inhibition Using an Automated, Bioluminescent Histone Deacetylase I/II Assay

CELL HEALTH. reliable cell viability data. instant time savings. PrestoBlue Cell Viability Reagent

Use of Echo Liquid Handlers to Improve the Efficiency and Reliability of Bioassay Laboratories

PromoFectin-HUVEC Cell Transfection Reagent. Instruction Manual. Cat.No. PK-CT-2000-HUV-10 PK-CT-2000-HUV-50

EarlyTox Cell Integrity Kit

University of Pennsylvania Perelman School of Medicine High Throughput Screening Core

ApoTox-Glo Triplex Assay

Data Sheet. TCR activator / PD-L1 - CHO Recombinant Cell line Cat. #: 60536

Using the xcelligence RTCA SP Instrument to Perform Cytotoxicity Assays

Transcreener PDE Assay

Data Sheet. Hippo Pathway TEAD Reporter MCF7 Cell Line Catalog #: 60618

Research. Image FlashPlate

Data Sheet PD-1 / NFAT - Reporter - Jurkat Recombinant Cell Line Catalog #: 60535

Development and Utilization of Bromodomain and Extra Terminal Domain (BET) Assays Using AlphaLISA Technology

addresses: and

Shehab. Yousef... Omar. Yousef Omar. Anas

Z -LYTE KINASE ASSAY KIT SER/THR 9 PEPTIDE PROTOCOL

Using the xcelligence RTCA SP Instrument to Perform GPCR Assays

Tyrosine Kinase Assay Kit, Red*

This product is exclusively for research and for in-vitro application. It should not be used for therapeutic and diagnostic applications in humans.

How To Choose a GeneCopoeia Luciferase System. Ed Davis, Ph.D.

Kinetic measurement of cytotoxicity using CellTox Green Cytotoxicity Assay on the IncuCyte TM FLR or ZOOM

Cytotoxicity assays: Principles and Applications

Measuring Cell Proliferation and Cytotoxicity using the ATPlite 1step System and the VICTOR Nivo Multimode Plate Reader

Data Sheet. SBE Reporter Kit (TGFβ/SMAD signaling pathway) Catalog #: 60654

Inhibitors of Mycobacterium tuberculosis DosRST signaling and persistence

Prioritizing the Toxicity Testing of Environmental Chemicals at EPA

Avalanche -Omni Transfection Reagent

Simplifying Kinase Profiling Using ADP Detection with the Transcreener Kinase Assay Introduction Figure 1. Transcreener Kinase Assay Principle

Avalanche -Everyday Transfection Reagent

How to overcome the challenges presented by bioassays

Avalanche -Omni Transfection Reagent

Data Sheet. Hedgehog Signaling Pathway Gli Reporter NIH3T3 Cell Line Catalog #: 60409

ratmrp2 PREDIVEZ Protocol CAT. NO. SBPV03

MATERIAL DATA SHEET. Reagents Provided in Kit

MATERIAL DATA SHEET. Reagents Provided in Kit

ab MDR Assay Kit (Fluorometric)

FlashPlate File #13. A Homogeneous Protein Kinase Assay Performed on 384-Well Streptavidin-Coated FlashPlate HTS PLUS. High Throughput Screening

Cellular High Throughput Screening assays using HTRF detection of cytokines

Impact of Standardizing on Traceable QC for Volume Transfers Artel

A Cost-effective Workflow for High-Throughput Screening of G- Protein Coupled Receptors (GPCRs)

FAR RED FP. GDP FP Assay. Technical Manual. v071814

Measuring Wound Healing and Cell Migration using Celigo Imaging Cytometer

TAG-LITE RECEPTOR LIGAND BINDING ASSAY

Data Sheet. Hedgehog Signaling Pathway Gli Reporter NIH3T3 Cell Line Catalog #: 60409

Cell Viability Assay Kit (Bioluminescent)

The BioFlux 200 System Using Well Plate Microfluidics for Live Cell Assays Product Overview and Tutorial

Calcium Assay Kit. Technical Data Sheet. Product Information. Description. Storage. Materials not included

Pre-made Reporter Lentivirus for p53 Signal Pathway

Transcription:

THE JOURNAL OF UNDERGRADUATE RESEARCH University of Kansas Fall 2009 The Viability of Cancerous vs. Non-cancerous Cells Lung cancer is a disease that affects a number of human beings in the world each and every day. It is the number one cancer-related cause of death in men, and the number two cancer-related cause of death in women. It also has a high mortality rate when compared to other cancers. These factors, combined with the high-profile nature of cancer make it imperative that we study this disease and find ways to defeat it. My research with the University of Kansas High Throughput Screening laboratory is the beginning of finding ways to defeat this disease. Every drug on the market has some mode of action. A compound will bind to a receptor, or block the synthesis of another compound, or act in some way that affects the cell. Here, we are looking for the differences that cancerous and non-cancerous cells have. With this research, we can find compounds that inhibit the growth of cancerous cells, and do not inhibit the growth of non-cancerous cells, and then find common modes of action for those compounds. If there is a common mode throughout many different compounds, then that mode of action can be isolated and further researched for drug delivery. In my specific work, we used two different lung cell types: the MRC-5 cell line, which is a normal lung fibroblast, and the A-549, which is a cancerous lung cell. These were not identical cell lines, as they did not originate from the same human being, but they were close matches. The way we decided to approach the problem is to use a cell-based assay to inject the compounds into the cells, and then measure the cells growth. To find the effects the compounds had on the cells, we needed some way to visualize the viability of the cell lines. To do this, we used the reagent Cell Titer-Glo. This reagent reacts with the amount of ATP present, and luminesces at different intensities corresponding to the amount of ATP. Therefore, if many cells were to survive, the luminescence value would be very high and, contrastingly, if the cells were to die, then the values would be lower. However, before this reagent could be used, preliminary experiments had to be performed. The first experiment to be performed was to obtain growth curves LOGAN NICKELS is a senior in Biochemistry at the University of Kansas. 85

Figure 1. This is the growth curve of the non-cancerous MRC-5 cell line, with an ideal plating density of 1,500 cells / well of a 384-well plate. for both cell lines. This would allow us to not only find the optimal seeding density for both lines, but to also associate specific luminescence values with specific numbers of cells. This was done by using a hemocytometer to place a specific number of cells within a well of a standard 384-well plate, and using the Cell Titer-Glo reagent combined with the Tecan Safire, 2 a device that measures luminescence values, a luminescence value for that number of cells could be obtained. When that was done, the cells were then plated at specific densities, and allowed to grow. The plates were read with the Cell Titer-Glo reagent every 24 hours, and the luminescence values noted. Since the luminescence values could only be obtained using black plates, a separate set of cells were plated in clear plates, and using a photographic microscope, a good visual representation of the different densities could be obtained as well. The plates with the higher seeding densities began to show cell death after 48 hours, and the lower seeding densities continued to grow. After the full 4 days of growth, the results showed that the optimal seeding density for both the MRC-5 cell line and the A-549 cell line was 1,500 cells per well. This would allow the cells to grow to full confluency over the four days of the project, but not experience cell death due to overconfluency. If the cells are overly confluent, then they 86

Figure 2. This graph shows the growth curve of the cancerous A-549 cells, which have an ideal plating density of 1,500 cells / well of a 384-well plate. begin to stack on top of each other, use all of their nutrients, and die in their own waste. This would skew the results of the final project, so it was imperative that we find the proper seeding density. The second experiment to be performed before the actual assay was a toxicity screen. The compounds used in the screen were stored in 384-well polypropylene plates. The plates contained 20 µl of compound FIgure 3. Day 1 of the highest seeding density, 16,000 cells / well of the MRC-5 line FIgure 4. Day 4 of the A-549 1,000 cells / well density, nearing confluency 87

Figure 5. This graph plots the number of compounds vs. their percentages away from normalized values. Overall, there were 79 compounds that were at least 50% below the normalized value, and 103 compounds at least 50% above the normalized value, for a total of 182 compounds classified as active. Of the 103 active compounds above 50% of the normalized value, 69 of them were of suspiciously high values, and in a concentrated area of one plate, possibly indicating a liquid handling error. in each well, frozen in 2.25% DMSO in water. Since DMSO is toxic to cells, this test was required to ensure that addition of compound would only induce toxicity due to the effects of compound, not DMSO. By adding different concentrations of DMSO to cell lines, the cell viability was observed by using Cell Titer-Glo and the Tecan Safire2, as in the growth curve experiment. By comparing the luminescence values obtained with the DMSO lines to the growth curve, cell viability was easily established. Since after compound addition, the cells would be in approximately 0.65% DMSO, as long as the cell lines were viable in that concentration of DMSO, then the screen could proceed as planned. To accomplish this, two black plates were seeded with 1,500 cells per well, one plate of each cell type. This seeding density was found previously in the growth curve experiment. These plates were allowed to grow for two days, and then, as per the protocol for the final assay, a mock compound was added, using the BioMek FX robotic system. This mock compound was simply a salt solution with different concentrations across the board. After addition, the concentrations of DMSO ranged from 0.0%, all the way to 4.0%. This would allow for reliability of results, and a great range of DMSO toxicity results. After the addition of the mock compound, the cells were grown another two days, and then read using Cell Titer-Glo and the Tecan Safire2. The results showed that for both cell lines, the DMSO concentration used in the final assay was well within safe levels, and that the non-cancerous line did not show signs of toxicity until a concentration of 2%. The cancerous line, however, seemed to be more hardy than the non-cancerous line, not showing signs of toxicity until a concentration of nearly 4%. 88

After these experiments were performed, the final cell assay could continue. The optimal cell densities had been set, luminescence values could be traced back to actual cell numbers, and the DMSO concentration being used in the final assay was not toxic. The cells were plated at their optimal densities in black 384- well plates, and then grown for two days before compound addition. The compounds used came from different libraries, compiled by different laboratories. The libraries used in the screen were the Prestwick (Prestwick Chemical, Illkirch, France) and the Spectrum Collection (Microsource Discovery Systems, Inc., Gaylordsville, CT) libraries, which contain a very small fraction of the total compounds available to the KU HTS lab. The reason for the small selection of compounds was, again, a time limitation associated with the constraints of an independent study. These libraries consist of small molecules with known biological activity. The purpose of these libraries is to see how compounds with a variety of biological activities behave in an assay. Thus, their purpose is more for assay development than for finding lead molecules. After compound addition using the BioMek FX system, the cells were then grown for another two days, to reach full confluency within their wells. They were then read using the same method of Cell Titer-Glo and the Tecan Safire2 seen in the preliminary experiments. After reading the plates, the data was collected, and normalized so that the difference in growth could be easily seen. Again, the point was to find compounds that adversely affected the growth of the cancerous cell line, but caused no harm to the non-cancerous cell line. For a compound to be classified as active, there needed to be a difference of at least 50% in the growth of the two lines. The data was then analyzed to find the compounds that differed by at least 50% in growth, and the specific compounds noted. The screen indicated 182 compounds of interest that should be investigated further, as their effects differed by more than 50%. Figure 6. This graph shows the overall effect of certain plates on the cell lines. A positive number means that the plate had an effect that caused toxicity in the cancerous cell line more than the normal cell line, and a negative number means that the normal cell line was more affected than the cancerous line. Plate A001 had a number of abnormalities that could have caused the plate to look as if was more toxic to the cancerous cell line than it actually was. 89

Unfortunately, due to the time constraints of a student independent study, this work will have to be continued at a later date. The next step with these compounds is to confirm their activity, and ensure that they are not false positives / negatives. Unfortunately, many false positives / negatives are expected during the checks, as there were pipetting errors with the robotic addition system used in the experiment. The next step includes performing the experiment again in the areas that were deemed problematic, and comparing those results against the original results to find false positives and negatives. Compounds that are confirmed as active should be used in dose-response experiments, to show the potency of the compounds. After dose-response curves have been calculated, the compounds should be used in other assays to determine the mechanism of action for the drugs. There are a number of assays to perform with the drugs, such as apoptosis assays, cellcycle arrest assays, and cytoskeletal assays. Once the mechanism of action is determined, the compounds can be used with toxicity mechanisms to develop new drug targets. Despite this being only the first, small step in fighting cancer, hopefully we can soon find a way to make these compounds deliverable to human beings, and eventually help those in need. 90